Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio

LEOBENDORF, Austria, September 02, 2026--Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation.

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).

Securities Class Action Lawsuit Filed Against Fractyl Health, Inc. ...

(PR-inside.com) NEW YORK, NY / ACCESS Newswire / September 2, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ..

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

Encoded Therapeutics to Present New Data on ETX101 Gene Therapy for Dravet Syndrome at the 16th European Epilepsy Congress

SOUTH SAN FRANCISCO, Calif., September 02, 2026--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that new results from the POLARIS clinical program of ETX101, its investigational AAV9-based gene regulation therapy for SCN1A+ Dravet syndrome, will be featured in a platform presentation at the 16th European Epilepsy Congress on September 7, 2026, in Athens, Greece.

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company's intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technology Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technology

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor conferences.

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

WATERTOWN, Mass., September 02, 2026--Treeline Biosciences, Inc. ("Treeline") today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-121, Treeline's BCL6 degrader, in combination with Roche’s CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in separate combination cohorts for patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL).

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings...

AI in Medical Imaging Market: North America Leads While Asia Pacific Builds the Next Growth Engine

Researchers at DeepC and the Technical University of Munich’s neuroradiology department ran a study that quietly explains why the AI in medical imaging market is [read full press release...]

When Physical Therapy Ends but the Pain Doesn't: WOS Performance Clinic Offers Physician-Led Evaluations in Eugene